Erratum
After publication of the original article [1], an error was noticed within the title: acronym “REBECCA” was erroneously written as “REBACCA”. The original article has now been updated with the correct title which can also be found above. The publisher would like to apologise for this error and for any inconvenience this may have caused.
References
Adenis A, de la Fouchardiere C, Paule B, Burtin P, Tougeron D, Wallet J, et al. Survival, safety, and prognostic factors for outcome with Regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: results from a multicenter study (REBECCA) nested within a compassionate use program. BMC Cancer. 2016;16:412. doi:10.1186/s12885-016-2440-9.
Author information
Authors and Affiliations
Corresponding author
Additional information
The online version of the original article can be found under doi:10.1186/s12885-016-2440-9.
Rights and permissions
Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
About this article
Cite this article
Adenis, A., de la Fouchardiere, C., Paule, B. et al. Erratum to: Survival, safety, and prognostic factors for outcome with Regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: results from a multicenter study (REBECCA) nested within a compassionate use program. BMC Cancer 16, 518 (2016). https://doi.org/10.1186/s12885-016-2559-8
Received:
Accepted:
Published:
DOI: https://doi.org/10.1186/s12885-016-2559-8